63159

PvDBP Mutations and Copy Numbers of Plasmodium vivax from Duffy negatives: Association with Erythrocyte Invasion and Clinical Diseases

Favorite this paper

Plasmodium vivax invasion of human erythrocytes depends on the Duffy Binding Protein (PvDBP) that recognizes and interacts with the Duffy antigen. In Ethiopia, individuals with Duffy negative blood group accounts for approximately 30% of the population. In malaria-endemic area, P. vivax prevalence among Duffy negatives is nearly 2%. Our recent study indicated that mutations in PvDBP1 does not account for the ability of P. vivax to infect Duffy null individuals, but duplication or expansion of thegene may allow low affinity binding to another receptor on Duffy null erythrocytes. Two distinct types of PvDBP duplication have been detected, respectively, in Madagascar and Cambodia. However, the prevalence and extent of PvDBP duplications in sub-Saharan Africa, as well as its epidemiological significance is unknown. We used quantitative real-time PCR and whole genome sequencing to detect PvDBP gene copy number in P. vivax isolated from Duffy negative homozygotes (FY*BES/*BES) and heterozygotes (FY*A/*BESor FY*B/*BES) and compare with the Duffy positives (FY*A/*A, FY*B/*B, or FY*A*B). PvDBP expansion was detected in 97 of 150 (64%) Ethiopian isolates. PvDBP copy number was found to be remarkably variable compared to other geographical isolates, ranging from 1- 9 copies. High copy PvDBP was detected in P. vivax from the two Duffy negative patients. PvDBP copy number is significantly different between symptomatic and asymptomatic infections, but not correlated with age and parasitemia. Expansion of PvDBP and its high prevalence in Ethiopia may associate to novel ligand-receptor interaction between the parasite and the host. Further, we used an Illumina Hi-Seq sequencing platform to obtain whole genome sequence of P. vivaxisolated from a Duffy-negative patient in Ethiopia. Between 16 and 322 million pair-end 150-bp reads were generated for 11 Ethiopian P. vivax samples, including one from a Duffy-negative and 10 from Duffy-positive patients. A range of 10-95% of the reads was mapped to PvP01, a new P. vivax reference genome sequence generated from an Indonesian isolate. Average P. vivax genome coverage was 28-582× and over 95% of the genome was covered by at least 15 reads for all 11 samples. Over 80 million reads were generated for the Duffy-negative P. vivax sample, and 63% of which were mapped to the P. vivax reference genome resulting in 106x average coverage. Polymorphisms in genome structure and position will be discussed in the context of their functional significance in erythrocyte binding. Our study presents a step forward to understanding the genetic mechanisms ofP. vivax invasion in Duffy-negative erythrocytes. Such knowledge is valuable to predict the potential threat of P. vivax infection in Duffy-negative dominant Africa.Plasmodium vivax invasion of human erythrocytes depends on the Duffy Binding Protein (PvDBP) that recognizes and interacts with the Duffy antigen. In Ethiopia, individuals with Duffy negative blood group accounts for approximately 30% of the population. In malaria-endemic area, P. vivax prevalence among Duffy negatives is nearly 2%. Our recent study indicated that mutations in PvDBP1 does not account for the ability of P. vivax to infect Duffy null individuals, but duplication or expansion of thegene may allow low affinity binding to another receptor on Duffy null erythrocytes. Two distinct types of PvDBP duplication have been detected, respectively, in Madagascar and Cambodia. However, the prevalence and extent of PvDBP duplications in sub-Saharan Africa, as well as its epidemiological significance is unknown. We used quantitative real-time PCR and whole genome sequencing to detect PvDBP gene copy number in P. vivax isolated from Duffy negative homozygotes (FY*BES/*BES) and heterozygotes (FY*A/*BESor FY*B/*BES) and compare with the Duffy positives (FY*A/*A, FY*B/*B, or FY*A*B). PvDBP expansion was detected in 97 of 150 (64%) Ethiopian isolates. PvDBP copy number was found to be remarkably variable compared to other geographical isolates, ranging from 1- 9 copies. High copy PvDBP was detected in P. vivax from the two Duffy negative patients. PvDBP copy number is significantly different between symptomatic and asymptomatic infections, but not correlated with age and parasitemia. Expansion of PvDBP and its high prevalence in Ethiopia may associate to novel ligand-receptor interaction between the parasite and the host. Further, we used an Illumina Hi-Seq sequencing platform to obtain whole genome sequence of P. vivaxisolated from a Duffy-negative patient in Ethiopia. Between 16 and 322 million pair-end 150-bp reads were generated for 11 Ethiopian P. vivax samples, including one from a Duffy-negative and 10 from Duffy-positive patients. A range of 10-95% of the reads was mapped to PvP01, a new P. vivax reference genome sequence generated from an Indonesian isolate. Average P. vivax genome coverage was 28-582× and over 95% of the genome was covered by at least 15 reads for all 11 samples. Over 80 million reads were generated for the Duffy-negative P. vivax sample, and 63% of which were mapped to the P. vivax reference genome resulting in 106x average coverage. Polymorphisms in genome structure and position will be discussed in the context of their functional significance in erythrocyte binding. Our study presents a step forward to understanding the genetic mechanisms ofP. vivax invasion in Duffy-negative erythrocytes. Such knowledge is valuable to predict the potential threat of P. vivax infection in Duffy-negative dominant Africa.